These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 23696633)

  • 1. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1.
    Sieper J; Lenaerts J; Wollenhaupt J; Rudwaleit M; Mazurov VI; Myasoutova L; Park S; Song Y; Yao R; Chitkara D; Vastesaeger N;
    Ann Rheum Dis; 2014 Jan; 73(1):101-7. PubMed ID: 23696633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2.
    Sieper J; Lenaerts J; Wollenhaupt J; Rudwaleit M; Mazurov VI; Myasoutova L; Park S; Song Y; Yao R; Chitkara D; Vastesaeger N;
    Ann Rheum Dis; 2014 Jan; 73(1):108-13. PubMed ID: 23740231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
    Sieper J; Rudwaleit M; Lenaerts J; Wollenhaupt J; Myasoutova L; Park SH; Song YW; Yao R; Huyck S; Govoni M; Chitkara D; Vastesaeger N
    Rheumatology (Oxford); 2016 Nov; 55(11):1946-1953. PubMed ID: 27411482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial.
    Poddubnyy D; Listing J; Sieper J
    Arthritis Rheumatol; 2016 Aug; 68(8):1899-903. PubMed ID: 27015283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The concept of axial spondyloarthritis. Lessons from the INFAST study.
    Zeidler H
    Ann Rheum Dis; 2014 Apr; 73(4):e18. PubMed ID: 24318860
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis.
    Barkham N; Keen HI; Coates LC; O'Connor P; Hensor E; Fraser AD; Cawkwell LS; Bennett A; McGonagle D; Emery P
    Arthritis Rheum; 2009 Apr; 60(4):946-54. PubMed ID: 19333933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
    Sieper J; van der Heijde D; Dougados M; Maksymowych WP; Scott BB; Boice JA; Berd Y; Bergman G; Curtis S; Tzontcheva A; Huyck S; Weng HH
    Arthritis Rheumatol; 2015 Oct; 67(10):2702-12. PubMed ID: 26139307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to H Zeidler's comments on the INFAST study.
    Sieper J
    Ann Rheum Dis; 2014 Apr; 73(4):e19. PubMed ID: 24470538
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
    Dougados M; Wood E; Combe B; Schaeverbeke T; Miceli-Richard C; Berenbaum F; Koppiker N; Dubanchet A; Logeart I
    Arthritis Res Ther; 2014 Nov; 16(6):481. PubMed ID: 25428762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis.
    Pérez-Guijo VC; Cravo AR; Castro Mdel C; Font P; Muñoz-Gomariz E; Collantes-Estevez E
    Joint Bone Spine; 2007 May; 74(3):254-8. PubMed ID: 17387031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
    Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study.
    Dougados M; van der Heijde D; Sieper J; Braun J; Citera G; Lenaerts J; van den Bosch F; Wei JC; Pedersen R; Bonin R; Jones H; Marshall L; Logeart I; Vlahos B; Bukowski JF; Maksymowych WP
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1590-1598. PubMed ID: 28482137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Golder W; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Reddig J; Sieper J
    Arthritis Rheum; 2003 Aug; 48(8):2224-33. PubMed ID: 12905476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
    Landewé R; Braun J; Deodhar A; Dougados M; Maksymowych WP; Mease PJ; Reveille JD; Rudwaleit M; van der Heijde D; Stach C; Hoepken B; Fichtner A; Coteur G; de Longueville M; Sieper J
    Ann Rheum Dis; 2014 Jan; 73(1):39-47. PubMed ID: 24013647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local infliximab injection of sacroiliac joints in non-radiographic axial spondyloarthritis: Impact on clinical and magnetic resonance imaging parameters of disease activity.
    Soliman E; El-Tantawi G; Matrawy K; Aldawoudy A; Naguib A
    Mod Rheumatol; 2015 May; 25(3):421-6. PubMed ID: 25401227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
    Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
    Sieper J; van der Heijde D; Dougados M; Mease PJ; Maksymowych WP; Brown MA; Arora V; Pangan AL
    Ann Rheum Dis; 2013 Jun; 72(6):815-22. PubMed ID: 22772328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis.
    Dougados M; Wood E; Gossec L; Dubanchet A; Logeart I; van der Heijde D
    J Rheumatol; 2015 Dec; 42(12):2361-8. PubMed ID: 26568588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.
    Gensler LS; Chakravarty SD; Cameron C; Peterson S; Spin P; Kafka S; Nair S; Deodhar A
    Clin Rheumatol; 2020 Oct; 39(10):2907-2917. PubMed ID: 32367407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.